BRPI0515175A - método para radiofluoração, composto, composição radiofarmacêutica, uso de um conjugado radiorrotulado ou um sal do mesmo, método para diagnose ou formação de imagem in vivo de uma doença ou condição associada com a angiogênese, e, método para monitorar o efeito do tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer - Google Patents

método para radiofluoração, composto, composição radiofarmacêutica, uso de um conjugado radiorrotulado ou um sal do mesmo, método para diagnose ou formação de imagem in vivo de uma doença ou condição associada com a angiogênese, e, método para monitorar o efeito do tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer

Info

Publication number
BRPI0515175A
BRPI0515175A BRPI0515175-9A BRPI0515175A BRPI0515175A BR PI0515175 A BRPI0515175 A BR PI0515175A BR PI0515175 A BRPI0515175 A BR PI0515175A BR PI0515175 A BRPI0515175 A BR PI0515175A
Authority
BR
Brazil
Prior art keywords
condition associated
salt
combat
disease
animal body
Prior art date
Application number
BRPI0515175-9A
Other languages
English (en)
Inventor
Magne Solbakken
Bente Arbo
Alan Cuthbertson
Alexander Gibson
Original Assignee
Ge Healthcare As
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare As, Ge Healthcare Ltd filed Critical Ge Healthcare As
Publication of BRPI0515175A publication Critical patent/BRPI0515175A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

MéTODO PARA RADIOFLUORAçãO, COMPOSTO, COMPOSIçãO RADIOFARMACêUTICA, USO DE UM CONJUGADO RADIORROTULADO OU UM SAL DO MESMO, MéTODO PARA DIAGNOSE OU FORMAçãO DE IMAGEM IN VIVO DE UMA DOENçA OU CONDIçãO ASSOCIADA COM A ANGIOGêNESE, E, MéTODO PARA MONITORAR O EFEITO DO TRATAMENTO DE UM CORPO HUMANO OU ANIMAL COM UM MEDICAMENTO PARA COMBATER UMA CONDIçãO ASSOCIADA COM CáNCER A invenção refere-se a conjugados de fórmula (III) ou (IIIa),ou um sal do mesmo, seu uso como radiofarmacêuticos, processos para sua preparação, e intermediários sintéticos usados em tais processos.
BRPI0515175-9A 2004-09-14 2005-09-14 método para radiofluoração, composto, composição radiofarmacêutica, uso de um conjugado radiorrotulado ou um sal do mesmo, método para diagnose ou formação de imagem in vivo de uma doença ou condição associada com a angiogênese, e, método para monitorar o efeito do tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer BRPI0515175A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0420344.4A GB0420344D0 (en) 2004-09-14 2004-09-14 Diagnostic compounds
PCT/IB2005/002727 WO2006030291A2 (en) 2004-09-14 2005-09-14 Radiofluorinated peptides

Publications (1)

Publication Number Publication Date
BRPI0515175A true BRPI0515175A (pt) 2008-07-08

Family

ID=33186989

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515175-9A BRPI0515175A (pt) 2004-09-14 2005-09-14 método para radiofluoração, composto, composição radiofarmacêutica, uso de um conjugado radiorrotulado ou um sal do mesmo, método para diagnose ou formação de imagem in vivo de uma doença ou condição associada com a angiogênese, e, método para monitorar o efeito do tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer

Country Status (23)

Country Link
US (2) US7875701B2 (pt)
EP (1) EP1791571B1 (pt)
JP (1) JP4949251B2 (pt)
KR (1) KR101243016B1 (pt)
CN (1) CN101151054B (pt)
AT (1) ATE404225T1 (pt)
AU (1) AU2005283904B8 (pt)
BR (1) BRPI0515175A (pt)
CA (1) CA2578470C (pt)
DE (1) DE602005008996D1 (pt)
DK (1) DK1791571T3 (pt)
ES (1) ES2312018T3 (pt)
GB (1) GB0420344D0 (pt)
IL (1) IL181529A (pt)
MX (1) MX2007003019A (pt)
NO (1) NO20071880L (pt)
NZ (1) NZ553384A (pt)
PL (1) PL1791571T3 (pt)
PT (1) PT1791571E (pt)
RU (1) RU2396272C9 (pt)
SI (1) SI1791571T1 (pt)
WO (1) WO2006030291A2 (pt)
ZA (1) ZA200702700B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230901B1 (hu) * 2001-07-10 2019-01-28 Ge Healthcare Limited Peptidalapú vegyületek és ezeket tartalmazó gyógyszerkészítmények
EP1985624A3 (en) * 2007-04-23 2008-12-24 Bayer Schering Pharma Aktiengesellschaft Single step method of radiofluorination of biologically active compounds or biomolecules
CA2663454C (en) * 2006-09-15 2015-04-21 Siemens Medical Solutions Usa, Inc. Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins
WO2008072976A2 (en) * 2006-12-13 2008-06-19 Ge Healthcare As Synthesis of a radiofluorinated peptide using microwave activation technology
WO2008075966A2 (en) * 2006-12-18 2008-06-26 Ge Healthcare As Synthesis of a radiofluorinated peptide using photolabile protecting groups
EP2114464A2 (en) * 2006-12-28 2009-11-11 GE Healthcare AS Radiofluorination methods
KR20090119966A (ko) * 2007-03-01 2009-11-23 바이엘 쉐링 파마 악티엔게젤샤프트 진단 영상화제로서의 18ｆ 플루오로-벤조일 표지된 생물학적 활성 화합물, 벤조트리아졸-1-일옥시-벤조일, 2,5-디옥소-피롤리딘-1-일옥시)벤조일 및 트리메틸암모니오-벤조일 전구체
EP2195037A2 (en) * 2007-09-10 2010-06-16 GE Healthcare UK Limited Radiofluorination methods
JP5399422B2 (ja) * 2008-02-28 2014-01-29 ジーイー・ヘルスケア・リミテッド 市販の安価な化学薬品からのｐｅｇ−６成分の合成
GB0905438D0 (en) * 2009-03-30 2009-05-13 Ge Healthcare Ltd Radiolabelling reagents and methods
US8834839B2 (en) * 2009-04-27 2014-09-16 General Electric Company Labeled molecular imaging agents, methods of making and methods of use
GB0910013D0 (en) * 2009-06-10 2009-07-22 Ge Healthcare Ltd PET imaging of fibogenesis
WO2011084763A1 (en) 2009-12-21 2011-07-14 Ge Healthcare Limited Borosilicate glassware and silica based qma's in 18f nucleophilic substitution: influence of aluminum, boron and silicon on the reactivity of the 18f ion
GB201013808D0 (en) * 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
CA2819347A1 (en) 2010-12-01 2012-06-07 Ge Healthcare Limited Radioconjugation method
US9180213B2 (en) 2010-12-09 2015-11-10 Ge Healthcare Limited Radiotracer compositions
BR112013015580A2 (pt) * 2010-12-21 2016-10-04 Ge Healthcare Ltd método de radioestabilização
US20130074758A1 (en) 2011-09-26 2013-03-28 Ocean Power Technologies, Inc. Anchoring apparatus for wave energy converters
WO2013048996A1 (en) 2011-09-30 2013-04-04 Ge Healthcare Limited Method for the purification of a peptide-based imaging agent precursor
WO2013048956A2 (en) * 2011-09-30 2013-04-04 Ge Healthcare Limited Solid phase extraction separation method
GB201202420D0 (en) * 2012-02-13 2012-03-28 Ge Healthcare Ltd Radiotracer compositions
GB201221266D0 (en) 2012-11-27 2013-01-09 Ge Healthcare Ltd Aldehyde compositions
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
KR102205845B1 (ko) 2013-10-28 2021-01-22 삼성전자주식회사 입자에 기반한 모델링 방법 및 장치
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
WO2016087653A1 (en) 2014-12-04 2016-06-09 Ge Healthcare Limited Method of removing acetaldehyde from radioactive pharmaceuticals
GB201518918D0 (en) * 2015-10-26 2015-12-09 Norsk Medisinsk Syklotronsenter As And Uni I Oslo Method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2165266C1 (ru) * 2000-06-28 2001-04-20 Центральный научно-исследовательский рентгенорадиологический институт Способ получения [2-18f]-2-дезоксиглюкозы
HU230901B1 (hu) * 2001-07-10 2019-01-28 Ge Healthcare Limited Peptidalapú vegyületek és ezeket tartalmazó gyógyszerkészítmények
GB0206750D0 (en) * 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
GB0317815D0 (en) 2003-07-30 2003-09-03 Amersham Health As Imaging agents

Also Published As

Publication number Publication date
EP1791571A2 (en) 2007-06-06
RU2007108762A (ru) 2008-10-27
PL1791571T3 (pl) 2009-01-30
AU2005283904B8 (en) 2012-02-23
PT1791571E (pt) 2008-11-19
DE602005008996D1 (de) 2008-09-25
RU2396272C2 (ru) 2010-08-10
KR20070053750A (ko) 2007-05-25
AU2005283904A1 (en) 2006-03-23
KR101243016B1 (ko) 2013-03-12
CN101151054A (zh) 2008-03-26
AU2005283904B2 (en) 2012-01-19
SI1791571T1 (sl) 2009-02-28
CN101151054B (zh) 2014-09-24
MX2007003019A (es) 2007-08-07
US20110117016A1 (en) 2011-05-19
US8563600B2 (en) 2013-10-22
NO20071880L (no) 2007-06-13
IL181529A0 (en) 2007-07-04
GB0420344D0 (en) 2004-10-13
ATE404225T1 (de) 2008-08-15
US20080095701A1 (en) 2008-04-24
CA2578470A1 (en) 2006-03-23
US7875701B2 (en) 2011-01-25
IL181529A (en) 2015-04-30
WO2006030291A3 (en) 2007-06-14
DK1791571T3 (da) 2008-12-08
EP1791571B1 (en) 2008-08-13
JP2008516894A (ja) 2008-05-22
CA2578470C (en) 2015-09-01
ZA200702700B (en) 2008-09-25
WO2006030291A2 (en) 2006-03-23
NZ553384A (en) 2011-02-25
ES2312018T3 (es) 2009-02-16
HK1118713A1 (en) 2009-02-20
JP4949251B2 (ja) 2012-06-06
RU2396272C9 (ru) 2010-12-10

Similar Documents

Publication Publication Date Title
BR0210886A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
Gandomkar et al. Clinical evaluation of antimicrobial peptide [99mTc/Tricine/HYNIC0] ubiquicidin 29–41 as a human-specific infection imaging agent
DE202014011600U1 (de) Markierte Inhibitoren des prostataspezifischen Membranantigens (PSMA), deren Verwendung als bildgebende Mittel und pharmazeutische Wirkstoffe für die Behandlung von Prostatakrebs
Wang et al. Synthesis and evaluation of 2-(3′-lodo-4′-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in alzheimer’s disease
CN112912731A (zh) 成纤维细胞活化蛋白(fap)靶向成像和纤维化治疗
UY27003A1 (es) Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
BR0110748A (pt) Plataforma de nanodispositivo multifuncional
AR050215A1 (es) Metodo para diagnosticar enfermedades utilizando copeptina.
WO2009143101A3 (en) Gastrin releasing peptide compounds
RU2007108762A (ru) Диагностические соединения
UY30419A1 (es) Nuevos benzoxazoles heteroaril sustituidos
Liu et al. Radiolabeled Zn-DPA as a potential infection imaging agent
BRPI0512209A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens de um corpo humano ou de animal por formação de imagem óptica, e de monitoração do efeito de tratamento de um corpo humano ou de animal com uma droga para combater uma condição associada com angiogênese
EP1706145A4 (en) AUTOANTIC BODY USED IN TUMOR IMAGING AND CANCER TREATMENT AS A CARRIER FOR PHARMACEUTICAL COMPOUNDS
BRPI0619251A2 (pt) compostos de ligação amilóide, composição farmacêutica e métodos de detecção de depósito(s) amilóides (s) in vivo, in vitro, de distinção de cérebro da doença de alzheimer de cérebro normal, de detecção e medição de depósitos amilóides em tecido de biópsia ou post-mortem humano ou animal, de ligação seletiva de composto de ligação amilóide, de identificação de paciente como prodrômico para doença associada com a deposição amilóide e de determinação da eficácia da terapia no tratamento da amiloidose
BRPI0917147B8 (pt) composto ou sal deste, uso de um composto ou sal deste, e, processo para fabricar um composto
WO2010051196A8 (en) Novel substituted azabenzoxazoles
WO2010096426A8 (en) Compounds, compositions, methods of synthesis, and methods of treatment
Gambini et al. Evaluation of 99mTc-glucarate as a breast cancer imaging agent in a xenograft animal model
Xu et al. Shortwave infrared fluorescence in vivo imaging of nerves for minimizing the risk of intraoperative nerve injury
Ordonez et al. Caspase-based PET for evaluating pro-apoptotic treatments in a tuberculosis mouse model
Lambrecht Evaluation of 99mTc-labeled antibiotics for infection detection
DE60033697D1 (de) Radiomarkierte vip-analoge zur diagnose und therapie
Q Shah et al. Synthesis of 99mTc-Rifabutin: a potential tuberculosis radiodiagnostic agent
MX2025010406A (es) Aglutinantes de alfa-sinucleina y metodos de uso

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 51/08 (2006.01)